Category: 3. Business

  • Boeing Company – Boeing, Airline Partners Set New Standard for Parts Authentication

    Boeing Company – Boeing, Airline Partners Set New Standard for Parts Authentication

    PLANO, Texas, Oct. 13, 2025 /PRNewswire/ — Boeing [NYSE: BA], in partnership with Southwest Airlines (SWA) and Aeroxchange Ltd., has successfully completed the aerospace industry’s first parts shipment accompanied by a digital 8130-3 certificate—an electronic version of the FAA-governed 8130-3 Authorized Release Certificate. This milestone advances supply chain security by preventing unapproved spare parts from entering the aerospace aftermarket.

    “This industry-first shipment reflects Boeing’s dedication to pursuing game-changing solutions through teamwork and partnership,” said William Ampofo, senior vice president, Parts & Distribution and Supply Chain, Boeing Global Services. “Together with Southwest Airlines and Aeroxchange, we are transforming how the industry ensures part authenticity and supply chain security.”

    The FAA Form 8130-3 certifies the airworthiness of aircraft parts, components and articles. The digital 8130 certificate replaces the traditional paper certificate with a secure, encrypted file that authenticates the authorized signer’s identity and ensures document integrity. Boeing led a pilot project to generate and gain authorization for this digital solution.

    Recently, a battery serviced at Boeing’s product repair services center in Davie, Florida, was the first part shipped using the electronic form, transmitted using the Aeroxchange eARC™ platform. Southwest Airlines received the battery at its Dallas facility, verifying its authenticity and airworthiness through the new digital process.

    “Southwest is proud to be a partner in the electronic process of document transfers and thrilled to be onsite for the very first delivery of a ship battery using this process. The security benefit of electronic forms aligns to Southwest’s value of a Safety-first culture and will be of significant benefit in the aviation industry,” said Landon Nitschke, senior vice president, Technical Operations, Southwest Airlines.

    “Aeroxchange is honored to have partnered with Boeing and Southwest Airlines to transmit this first ever eARC document providing a highly secure, verifiable digital record of the Authorized Release Certificate, Form 8130-3,” said Al Koszarek, president and CEO of Aeroxchange. “This landmark event is a milestone on the industry’s journey to prevent unapproved parts from entering the aviation supply chain.”

    Leveraging industry-leading X.509 security protocols, public/private key encryption, and blockchain-ready formats, the digital 8130 certificate creates an immutable, verifiable record of part authenticity throughout its lifecycle.

    Boeing will continue rolling out use of the digital 8130 certificate across all nine of its product repair services centers, as each center receives authorization from the FAA to use electronic systems for recordkeeping, electronic signatures and electronic manuals.

    Expanding the use of digital authorized release certificates was a key recommendation from the Aviation Supply Chain Integrity Coalition (ASCIC), a cross-industry group dedicated to preventing unapproved parts from entering the aviation supply chain. Boeing, Southwest Airlines and Aeroxchange are active members of the ASCIC.

    A leading global aerospace company and top U.S. exporter, Boeing develops, manufactures and services commercial airplanes, defense products and space systems for customers in more than 150 countries. Our U.S. and global workforce and supplier base drive innovation, economic opportunity, sustainability and community impact. Boeing is committed to fostering a culture based on our core values of safety, quality and integrity.  

    Contact
    Paula Horton
    Boeing Communications
    1-425-919-9351
    [email protected] 

    Boeing Media Relations
    [email protected]

    View original content:https://www.prnewswire.com/news-releases/boeing-airline-partners-set-new-standard-for-parts-authentication-302581242.html

    SOURCE Boeing

    Continue Reading

  • Self-harming behaviors among forensic psychiatric patients living with intellectual disability | BMC Psychiatry

    Self-harming behaviors among forensic psychiatric patients living with intellectual disability | BMC Psychiatry

  • Ray I, Simpson AIF, Jones RM, Shatokhina K, Thakur A, Mulsant BH. Clinical, demographic, and criminal behaviour characteristics of patients with intellectual disabilities in a Canadian forensic program. Front Psychiatry. 2019;10:760.eCollection 2019. https://doi.org/10.3389/fpsyt.2019.00760.

  • Chester V, Völlm B, Tromans S, Kapugama C, Alexander RT. Long-stay patients with and without intellectual disability in forensic psychiatric settings: comparison of characteristics and needs. BJPsych Open. 2018;4(4):226–34.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaggwa MM, Chaimowitz GA, Erb B, Prat S, Davids A, Moulden H, et al. Self-harming behaviors and forensic system-related factors: an analysis of the Ontario review board database. BMC Psychiatry. 2023;23(1):913.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Quinn S, Rhynas S, Gowland S, Cameron L, Braid N, S OC. Risk for intellectual disability populations in inpatient forensic settings in the united kingdom: A literature review. J Appl Res Intellect Disabil. 2022;35(6):1267–80.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Flygare Wallén E, Ljunggren G, Wahlström L, Pettersson D, Carlsson AC, Wändell P. The prevalence of self-harm and mental disorders among individuals with intellectual disabilities. Nord J Psychiatry. 2023;77(7):712–20.

    Article 
    PubMed 

    Google Scholar 

  • Duperouzel H, Fish R. Hurting no-one else’s body but your own: people with intellectual disability who self injure in a forensic service. J Appl Res Intellect Disabil. 2010;23(6):606–15.

    Article 

    Google Scholar 

  • Boylu ME, Taşdemir İ, Doğan M, Özcanlı T. Forensic psychiatric assessment in autism spectrum disorder: experience of a forensic psychiatry inpatient clinic from Türkiye. J Forensic Sci. 2024;69(6):2091–102.

    Article 
    PubMed 

    Google Scholar 

  • Boylu ME, Tasdemir I, Doğan M, Duran A. What is important in forensic psychiatric evaluation in people with down syndrome? A sample from Türkiye. J Intellect Disabil Offending Behav 2024;15.

  • Kaggwa MM, Chaimowitz GA, Erb B, Moulden H, Prat S, Davids A, Olagunju AT. Adverse childhood events and self-harming behaviours among individuals in Ontario forensic system: the mediating role of psychopathy. BMC Psychiatry. 2024;24(1):332.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bogaerts S, Spreen M, Ter Horst P, Gerlsma C. Predictive validity of the HKT-R risk assessment tool: two and 5-year violent recidivism in a nationwide sample of Dutch forensic psychiatric patients. Int J Offender Ther Comp Criminol. 2018;62(8):2259–70.

    Article 
    PubMed 

    Google Scholar 

  • Ssekitto JM, Abaatyo J, Namatovu A, Akatusasira R, Kibet E, Kamau SG, et al. Filicide in Africa: a systematic review. BMC Public Health. 2024;24(1):2125.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaggwa MM, Erb B, Prat S, Davids A, Bradford J, Chaimowitz GA, et al. Dual harm among patients in the Ontario forensic mental health system. PLoS ONE. 2025;19(12):e0316364.

    Article 

    Google Scholar 

  • Carr MJ, Steeg S, Mok PL, Pedersen CB, Antonsen S, Kapur N, et al. Adverse childhood experiences and risk of subsequently engaging in self-harm and violence towards other people—dual harm. Int J Environ Res Public Health. 2020;17(24):9409.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Martin J, Bureau J-F, Yurkowski K, Fournier TR, Lafontaine M-F, Cloutier P. Family-based risk factors for non-suicidal self-injury: considering influences of maltreatment, adverse family-life experiences, and parent–child relational risk. J Adolesc. 2016;49:170–80.

    Article 
    PubMed 

    Google Scholar 

  • McEvoy D, Brannigan R, Cooke L, Butler E, Walsh C, Arensman E, et al. Risk and protective factors for self-harm in adolescents and young adults: an umbrella review of systematic reviews. J Psychiatr Res. 2023. https://doi.org/10.1016/j.jpsychires.2023.10.017.

    Article 
    PubMed 

    Google Scholar 

  • Power J, Brown SL. Self-injurious behaviour: A review of the literature and implications for corrections. Correctional Service of Canada. 2010. https://www.canada.ca/en/correctional-service/corporate/library/research/report/216-full-report.html.

  • Marzano L, Fazel S, Rivlin A, Hawton K. Psychiatric disorders in women prisoners who have engaged in near-lethal self-harm: case–control study. Br J Psychiatry. 2010;197(3):219–26.

    Article 
    PubMed 

    Google Scholar 

  • Hawton K, Linsell L, Adeniji T, Sariaslan A, Fazel S. Self-harm in prisons in England and wales: an epidemiological study of prevalence, risk factors, clustering, and subsequent suicide. Lancet. 2014;383(9923):1147–54.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Favril L, Yu R, Hawton K, Fazel S. Risk factors for self-harm in prison: a systematic review and meta-analysis. Lancet Psychiatry. 2020;7(8):682–91.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Scott WP. Understanding the role of anger in self-harm: an interpretative phenomenological analysis. Doctoral thesis; City University London. 2006. https://openaccess.city.ac.uk/id/eprint/8490/.

    Google Scholar 

  • Laporte N, Klein Tuente S, Ozolins A, Westrin Å, Westling S, Wallinius M. Emotion regulation and self-harm among forensic psychiatric patients. Front Psychol. 2021. https://doi.org/10.3389/fpsyg.2021.710751.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Boylu ME, Görmez A, Turan Ş, Yeşilkaya ÜH, Boylu FB, Duran A. Offending and clinical characteristics of adults with autism spectrum disorder: experience at forensic psychiatry center in Türkiye between 2012 and 2022. Autism Res. 2025;18(1):110–21.

    Article 
    PubMed 

    Google Scholar 

  • Brown J, Beail N. Self-harm among people with intellectual disabilities living in secure service provision: a qualitative exploration. J Appl Res Intellect Disabil. 2009;22(6):503–13.

    Article 

    Google Scholar 

  • Fish RM. Working with people who harm themselves in a forensic learning disability service: experiences of direct care staff. J Learn Disabil. 2000;4(3):193–207.

    Article 

    Google Scholar 

  • Chaimowitz G, Moulden H, Upfold C, Mullally K, Mamak M. The Ontario forensic mental health system: a population-based review. Can J Psychiatry. 2022;67(6):481–9.

    Article 
    PubMed 

    Google Scholar 

  • Kaggwa MM, Davids A, Mohibi P, Erb B, Bradford J, Chaimowitz GA, et al. Weapon use during the index offense: a study among forensic psychiatry patients in Ontario, Canada. Inj Epidemiol. 2024;11(1):66.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Association WM. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.

    Article 

    Google Scholar 

  • Wechsler D. Wechsler Adult Intelligence Scale – Fourth Edition. (WAIS-IV) [Database record]. APA PsycTests. 2008.

  • Kaufman AS, Lichtenberger EO. Assessing adolescent and adult intelligence. 3rd ed. Hoboken, NJ, US: John Wiley & Sons Inc; 2006.

    Google Scholar 

  • Flinn LC, Hassett CL, Braham L. Development of forensic normative data for the WAIS-IV. J Forensic Pract. 2018;20(1):58–67.

    Article 

    Google Scholar 

  • Habets P, Jeandarme I, Uzieblo K, Oei K, Bogaerts S. Intelligence is in the eye of the beholder: investigating repeated IQ measurements in forensic psychiatry. J Appl Res Intellect Disabil. 2015;28(3):182–92.

    Article 
    PubMed 

    Google Scholar 

  • Iverson GL, Lange RT, Viljoen H, Brink J. WAIS-III general ability index in neuropsychiatry and forensic psychiatry inpatient samples ☆. Arch Clin Neuropsychol. 2006;21(1):77–82.

    Article 
    PubMed 

    Google Scholar 

  • Nazmie IF, Nebi MR, Zylfije Bekim H. Poor executive functioning associated with the risk of aggressive behavior recidivism in the forensic community in schizophrenic patients. Int J BioMed. 2013;3(2):94–9.

    Google Scholar 

  • de Keulen- Vos M, de Klerk A. Dutch forensic patients with and without intellectual disabilities: a comparison of demographic, offence, and diagnostic characteristics. Res Dev Disabil. 2022;126:104255.

    Article 

    Google Scholar 

  • Mitchell EH. The relationship between psychological response bias, neurocognitive performance validity, and estimates of IQ in criminal defendants. Doctoral dissertation, Rosalin Franklin University of Medicine and Science. 2014.

  • Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, Hessl D. Improving IQ measurement in intellectual disabilities using true deviation from population norms. J Neurodev Disord. 2014;6:1–15.

    Article 

    Google Scholar 

  • Kang H. Sample size determination and power analysis using the G*Power software. J Educ Eval Health Prof. 2021;18:17.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32(2):419–36.

    Article 
    PubMed 

    Google Scholar 

  • Bielska I, Ouellette-Kuntz H, Hunter D. Using national surveys for mental health surveillance of individuals with intellectual disabilities in Canada. Chron Dis Inj Can. 2012. https://doi.org/10.24095/hpcdp.32.4.03.

    Article 

    Google Scholar 

  • Matheson FI, Dastoori P, Whittingham L, Calzavara A, Keown LA, Durbin A, et al. Intellectual/developmental disabilities among people incarcerated in federal correctional facilities in Ontario, Canada: examining prevalence, health and correctional characteristics. J Appl Res Intellect Disabil. 2022;35(3):900–9.

    Article 
    PubMed 

    Google Scholar 

  • Gulati G, Kelly BD, Cusack A, Kilcommins S, Dunne CP. The experience of law enforcement officers interfacing with suspects who have an intellectual disability – a systematic review. Int J Law Psychiatry. 2020;72:101614.

    Article 
    PubMed 

    Google Scholar 

  • Nair R, Chen M, Dutt AS, Hagopian L, Singh A, Du M. Significant regional inequalities in the prevalence of intellectual disability and trends from 1990 to 2019: a systematic analysis of GBD 2019. Epidemiol Psychiatric Sci. 2022;31:e91.

    Article 
    CAS 

    Google Scholar 

  • Zhang T, Yin X, Chen H, Li Y, Chen J, Yang X. Global magnitude and temporal trends of idiopathic developmental intellectual disability attributable to lead exposure from 1990 to 2019: results from global burden of disease study. Sci Total Environ. 2022;834:155366.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Yang X, Liu C, Liu Y, He Z, Li J, Li Y, et al. The global burden, trends, and inequalities of individuals with developmental and intellectual disabilities attributable to iodine deficiency from 1990 to 2019 and its prediction up to 2030. Front Nutr. 2024. https://doi.org/10.3389/fnut.2024.1366525.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mendez B, Bozzay M, Verona E. Internalizing and externalizing symptoms and aggression and violence in men and women. Aggress Behav. 2021;47(4):439–52.

    Article 
    PubMed 

    Google Scholar 

  • Sadeh N, Javdani S, Finy MS, Verona E. Gender differences in emotional risk for self-and other-directed violence among externalizing adults. J Consult Clin Psychol. 2011;79(1):106.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Brown SA, Williams K, Collins A. Past and recent deliberate self-harm: emotion and coping strategy differences. J Clin Psychol. 2007;63(9):791–803.

    Article 
    PubMed 

    Google Scholar 

  • Fliege H, Lee J-R, Grimm A, Klapp BF. Risk factors and correlates of deliberate self-harm behavior: a systematic review. J Psychosom Res. 2009;66(6):477–93.

    Article 
    PubMed 

    Google Scholar 

  • Favina A, Abaatyo J, Kaggwa MM. Dual harm among patients attending a mental health unit in Uganda: a hospital based retrospective study. BMC Psychiatry. 2024;24(1):154.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Plener PL, Schumacher TS, Munz LM, Groschwitz RC. The longitudinal course of non-suicidal self-injury and deliberate self-harm: a systematic review of the literature. Borderline Personal Disord Emot Dysregul. 2015;2:1–11.

    Google Scholar 

Continue Reading

  • Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL

    Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL

    Patients with mantle cell lymphoma (MCL) treated with zanubrutinib (Brukinsa) in the community oncology setting achieved longer treatment durations, higher treatment adherence rates, and lower rates of treatment discontinuation compared with patients who received other BTK inhibitors, according to a real-world, retrospective, observational study of treatment patterns with BTK inhibitors, which was published in Future Oncology.1

    In total, 402 patients began treatment with ibrutinib (Imbruvica; n = 197; average follow-up, 746 days), acalabrutinib (Calquence; n = 161; average follow-up, 701 days) or zanubrutinib (n = 44; average follow-up, 493 days). Patients who received zanubrutinib had a significantly longer median duration of treatment, at 292 days, compared with those who received acalabrutinib (259 days) or ibrutinib (149 days; P < .01). Patients treated with zanubrutinib also displayed significantly better treatment adherence at more than 60, more than 90, more than 180, and more than 360 days compared with those who received acalabrutinib or zanubrutinib (P < .05). The rates of treatment adherence for more than 360 days in these respective cohorts were 53%, 45%, and 31%.

    Real-World Outcomes With BTK inhibitors in MCL: Key Takeaways

    • A real-world retrospective analysis found that patients with MCL treated with zanubrutinib had significantly longer median duration of treatment, higher treatment adherence, and the lowest rate of treatment discontinuation compared with those who received acalabrutinib or ibrutinib.
    • Although the study showed no significant differences in the incidence of clinical events between the cohorts during the 180-day follow-up period, patients in the zanubrutinib cohort had numerically lower rates of specific events like atrial fibrillation and fever compared with patients in the acalabrutinib and ibrutinib cohorts.
    • The results indicated strong outcomes for zanubrutinib in the post-BTK inhibitor setting, considering that 50% of the patients in the zanubrutinib group had a history of prior BTK inhibitor exposure before starting zanubrutinib treatment.

    Patients in the zanubrutinib cohort also had the lowest treatment discontinuation rate during follow-up, at 43.2% vs 45.2% in the ibrutinib cohort and 51.6% in the acalabrutinib cohort. The rates of treatment discontinuation due to toxicity in these respective cohorts were 13.6%, 13.2%, and 17.4%. The respective rates of treatment discontinuation due to nonresponse, disease progression, or worsened comorbidities were 18.2%, 24.9%, and 23.0%.

    “Overall, there were no significant differences between the BTK inhibitor cohorts in clinical events over the 180-day follow-up period,” lead study author Bijal Shah, MD, MS, and coauthors wrote in the paper. “However, the acalabrutinib and zanubrutinib cohorts generally had numerically lower rates of clinical events than the ibrutinib cohort. As the data mature, there could be an increase in time to next treatment and treatment duration for patients with MCL receiving zanubrutinib- or acalabrutinib-based treatment regimens.”

    Shah is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.

    What Are the Current Indications for BTK Inhibitors in MCL?

    In 2013, the FDA granted accelerated approval to ibrutinib for patients with MCL who had received at least 1 prior therapy.2 However, in 2023, this indication was voluntarily withdrawn by Johnson & Johnson and AbbVie citing insufficient data from the phase 3 SHINE confirmatory trial to support conversion to full approval.3 Furthermore,

    Furthermore, acalabrutinib is indicated in combination with bendamustine plus rituximab (Rituxan) for the treatment of adult patients with treatment-naive MCL who are ineligible for autologous stem cell transplant, as well as the treatment of adult patients with MCL who have received 1 or more prior lines of therapy.4 Additionally, zanubrutinib is approved for the treatment of adult patients who have received at least 1 prior therapy.5

    What Was the Design of the Real-World Retrospective Analysis of BTK Inhibitors in MCL?

    This retrospective analysis included electronic medical records from patients with MCL across 17 community oncology networks in the United States who began treatment with a BTK inhibitor between January 1, 2019, and November 30, 2021.1 Patients were followed for at least 6 months and examined for baseline characteristics and treatment outcomes.

    To be included in the study, patients were required to initiate a new BTK inhibitor–based regimen during the retrospective study index period and have at least 1 MCL diagnosis on the date of their first BTK inhibitor claim or during the pre-index period. Patients were excluded from the study if they were younger than 18 years of age at index, did not have a valid prescription or medical claim in the 3 months prior to the study index date, or did not have a valid prescription or medical claim in the 6 months following the study index date.

    Patients were stratified by the type of BTK inhibitor they initiated during the index period (acalabrutinib vs zanubrutinib vs ibrutinib). If patients began treatment with more than 1 BTK inhibitor–based regimen during this period, they were stratified based on a hierarchical approach.

    What Were the Baseline Characteristics of Patients Included in the Retrospective Analysis of BTK Inhibitors in MCL?

    Among all patients included in the study, 93% had received 1 or more systemic lines of therapy for MCL. In total, 50% of patients in the zanubrutinib group had a history of BTK inhibitor exposure prior to zanubrutinib; of these patients, 63.6% had received the previous BTK inhibitor within 60 days of initiating zanubrutinib.

    “The results of this analysis also show strong outcomes for zanubrutinib in the post-BTK inhibitor setting.”

    Additionally, 29.2% of patients in the acalabrutinib group had previously received another BTK inhibitor before acalabrutinib; 57.4% of these patients had received the prior BTK inhibitor within 60 days of initiating acalabrutinib. The study design required that no patients in the ibrutinib arm have a history of BTK inhibition prior to ibrutinib.

    At the start of study-specified BTK inhibitor therapy, the median ages of patients were similar between the zanubrutinib (75 years; range, 56-89), acalabrutinib (76 years; range, 36-89), and ibrutinib (72 years; range, 36-89) cohorts (P < .01). Furthermore, the percentages of patients who were at least 65 years of age were similar among the cohorts. Overall, investigators reported no significant differences across the cohorts regarding race, gender, ethnicity, or payer type.

    Regarding comorbidities, the incidence of chronic pulmonary disease during the pre-index period was significantly different between the zanubrutinib, acalabrutinib, and ibrutinib cohorts, at 25.0%, 16.8%, and 12.7%, respectively (P = .04). However, there were no significant differences among the cohorts regarding the prevalence of other prespecified comorbidities during the pre-index period, although patients in the zanubrutinib cohort had numerically highest rates of atrial fibrillation, cardiac arrhythmias, diabetes, gastroesophageal reflux disease, and renal disease. Conversely, patients in the acalabrutinib cohort had numerically the highest rates of cardiovascular disease and hypertension.

    What Additional Findings Were Seen in the Analysis of Real-World BTK Inhibitor Outcomes in MCL?

    During the 180-day follow-up period, no significant differences in the rates of clinical events between the cohorts were reported. Patients in the zanubrutinib cohort had the lowest rate of atrial fibrillation, at 9.1%, and no cases of atrial flutter were observed in this cohort. Additionally, the incidence of fever was lowest in the zanubrutinib arm, at 4.5% vs 12.4% in the acalabrutinib cohort and 16.8% in the ibrutinib cohort. Furthermore, the rates of myocardial infarction in these respective cohorts were 4.5%, 4.3%, and 7.6%.

    “Further analyses using more recent data and a longer time horizon are needed to validate these outcomes,” the authors concluded.

    References

    1. Shah BD, Xue M, Furnback W, Yang K. Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. Future Oncol. 2025;21(23):3043-3049. doi:10.1080/14796694.2025.2554354
    2. Imbruvica (ibrutinib) capsules now approved in the US for mantle cell lymphoma patients who have received at least one prior therapy. News release. Janssen Biotech, Inc. November 13, 2013. Accessed October 10, 2025. https://www.jnj.com/media-center/press-releases/imbruvica-ibrutinib-capsules-now-approved-in-the-us-for-mantle-cell-lymphoma-patients-who-have-received-at-least-one-prior-therapy
    3. Update on Imbruvica (ibrutinib) US accelerated approvals for mantle cell lymphoma and marginal zone lymphoma indications. News release. AbbVie. April 6, 2023. Accessed October 10, 2025. https://www.jnj.com/media-center/press-releases/update-on-imbruvica-ibrutinib-u-s-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications
    4. Calquence. Prescribing information. AstraZeneca; revised January 2025. Accessed October 10, 2025. https://drd9vrdh9yh09.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e2a005a7-65a0-4388-a671-dc887815a938/e2a005a7-65a0-4388-a671-dc887815a938_viewable_rendition__v.pdf
    5. Brukinsa. Prescribing information. BeOne; revised June 2025. Accessed October 10, 2025. https://d1e94vsyskgtht.cloudfront.net/brukinsa/pdfs/brukinsa-prescribing-information.pdf

    Continue Reading

  • Salesforce Investing $15B in San Francisco, the World’s AI Capital – Salesforce Investor Relations

    1. Salesforce Investing $15B in San Francisco, the World’s AI Capital  Salesforce Investor Relations
    2. Benioffs, Salesforce give $139 million to UCSF and AI education  San Francisco Chronicle
    3. Metallica and Benson Boone to headline San Francisco’s Dreamfest benefit concert  Dailyfly News
    4. Salesforce to Present Dreamfest, a Concert Benefiting UCSF Benioff Children’s Hospitals  San Francisco Examiner
    5. Benioffs and Salesforce donate $139 million to Bay Area healthcare and education  Investing.com

    Continue Reading

  • The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial | Stem Cell Research & Therapy

    The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial | Stem Cell Research & Therapy

    Isolation and characterization of WJ-MSC cells from UC

    After gaining informed consent, the university hospital used aseptic surgery to remove the umbilical cord tissue from a healthy donor. Before dissecting Wharton jelly (WJ), UC tissue was submerged in phosphate-buffered saline (PBS) containing 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 µg/ml amphotericin B [21]. WJ was centrifuged at 340xg after being treated for an hour at 37 °C with collagenase (1 mg/ml type I) and hyaluronidase (0.7 mg/ml). The cell pellet was mixed with DMEM/F12 supplemented with 15% FBS and incubated at 37 °C with 5% CO2. Fresh media was added to the cells every 4 days throughout the 21-day observation period [22]. WJ-MSC cells’ morphology was examined under a microscope. During the culture period, the medium was replaced every 3–4 days to ensure proper cell growth. Cells were split at a 1:4 ratio upon reaching confluence to maintain adequate growth conditions and prevent overcrowding. In WJ-MSC cells during the 21st-day passage, flow cytometric examination revealed the presence of CD14, CD34, CD73, and CD105 labeling. WJ-MSC cell surface receptors CD14, CD34, CD73, and CD105 staining were subjected to the immunofluorescence technique [23].

    Isolation and characterization of exosomes from WJ-MSC

    For 48 h, MSC cells were cultured in 75 cm2 flasks using DMEM/F12 mix that was devoid of FBS (starved). Exosomes secreted from fasting cells during a 48-h period were first obtained by collecting the media. To separate the cells and big vesicles, the fluids were centrifuged for 10 min at 13,000×g and 10 min at 45,000×g. After that, it was centrifuged in an ultracentrifuge for 5 h at 110,000×g (Beckman Coulter) [24]. Ultimately, the pellet was suspended in PBS and the supernatant was discarded [25]. Using flow cytometry, the characteristics of the isolated exosomes were examined for the CD9, CD63, CD81, and HSP70 markers. WJMSC exosomes were incubated with 1.5 × 105 anti-CD63 beads in 50 ml PBS at room temperature for 15 min to perform a flow cytometric analysis. The beads were incubated for the entire night at 4uC with mild stirring after the volume was increased to 300 ml. After 30 min of incubation in 100 mM glycine, the process was halted [26]. Following two rounds of washing, exosome-coated beads were incubated in 50 mg of human IgG (Sigma-Aldrich) for 15 min at 4 °C. They were then treated with anti-CD9 FITC, anti-CD63 PE, anti-CD81 APC, or matched isotype controls (BD Biosciences) and obtained using a FACS Melody (BD Biosciences) [27]. TEM electron microscopy was used to determine the morphology and nano-size of WJMSCs exosomes [28]. The isolation and characterization process were repeated three times to confirm reproducibility and consistency in results.

    Study design

    To assess the effectiveness and safety of WJ-MSC-derived exosome gel in patients with diabetic foot ulcers (DFUs), a randomized double-blind controlled clinical experiment was carried out. The trial protocol was implemented after obtaining the Scientific Research Ethics Committee of Kafr Elsheikh University on 25/3/2024, with final approval by the Committee’s decision No. KESIRB200-175. With Clinical Trial ID. NCT06812637 on ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06812637. All participants provided written informed consent before enrollment.

    Participants

    After 207 patients were assessed, 110 of them satisfied the requirements for inclusion. The patients were then split into three groups:

    1. a.

      Group treated: 40 patients received standard of care (SOC) once weekly for 4 weeks, followed by a 16-week follow-up, using Wharton jelly derived mesenchymal stem cell (WJ-MSC) exosome gel [29].

    2. b.

      Control group: 35 patients had just standard of care (SOC) for 4 weeks, then 16 weeks of follow-up.

    3. c.

      A visually similar saline-based formulation was administered once weekly to 35 patients in the placebo group for 4 weeks, followed by follow-up for 16 weeks, along with SOC [29].

    Analysis After Dropouts:

    • Group treated (SOC + WJ-MSC-derived exosome gel):

      • 30 patients completed the pre-protocol analysis.

      • Dropouts included: 3 withdrew consent, 1 missed 6 consecutive dressings, 5 were lost to follow-up, and 1 developed osteomyelitis.

    • Control Group (SOC only):

      • 24 patients completed the pre-protocol analysis.

      • Dropouts included: 5 withdrew consent, 2 missed 6 consecutive dressings, 2 were lost to follow-up, and 2 developed osteomyelitis.

    • Placebo Group (SOC with vehicle):

      • 31 patients completed the pre-protocol analysis.

      • Dropouts included: 1 death, 1 amputation,1 was lost to follow-up, and 1 developed osteomyelitis.

    A consort flow diagram showing the progress through the trial phases is shown in Fig. 1.

    Fig. 1

    Consort flow diagram showing the progress through the phases of the trial

    Inclusion criteria

    1. 1.

      People with type 2 diabetes who are 42–62 years of age.

    2. 2.

      The existence of a persistent DFU that does not go away after 7 days of standard of care (SOC) treatment or that does not shrink by more than 30%.

    3. 3.

      Ulcers smaller than 30 cm² that are seen on the plantar, medial, or lateral portions of the foot.

    4. 4.

      Individuals suffering from ischemic, neuropathic, or mixed neuropathic-ischemic ulcers.

    5. 5.

      Revascularization performed for ischemic ulcers before enrollment.

    Exclusion criteria

    1. 1.

      Pregnancy or breastfeeding.

    2. 2.

      Type 1 diabetes who are 18 years of age or older.

    3. 3.

      Presence of venous ulcers or active infections.

    4. 4.

      Exposure of bone, ligaments, or tendons.

    Demographic data, comorbidities, and concomitant medications were recorded. All participants received instructions on ulcer care and offloading.

    Methods of evaluation of ulcer treatment outcome

    Classification of ulcer

    Two systems were used for classification: the Wound, Ischemia, and Foot Infection system (WIFI system) and the Site, Ischemia, Neuropathy, Bacterial Infection, Area, Depth system (SINBAD system) [30].

    The SINBAD

    The SINBAD method makes it easier to classify diabetic foot ulcers (DFUs) using a 0–1 point scale. The severity of the ulcer is indicated by a score that ranges from 0 to 6 [31]. This approach is easy to use, gives good intra-observer and modest inter-observer repeatability, and doesn’t require any specific equipment beyond standard clinical examination. The SINBAD system is a useful tool for clinical application, as recommended by the IWGDF, and it efficiently monitors ulcer progression, healing, and amputation risk Table 1.

    The WIFI system

    The WIFI system, developed by the Society for Vascular Surgery in 2014, addresses the limitations of existing classifications by evaluating three major risk factors for amputation: wound characteristics, ischemia (based on ABI scores), and infection. Each factor is scored from 0 to 3, providing a detailed severity assessment as shown in Table 2. While the WIFI system aids in predicting major amputations and guiding interventions like revascularization, its reliance on specialized vascular measurements limits its utility in primary or community care settings, making it more suitable for specialized vascular clinics.

    To classify foot infection, we use the international working group on the diabetic foot (IWGDF)/Infectious diseases society of America (IDSA system) [32]

    The categorization method is used to determine whether a diabetic has a foot infection and how serious it is, as shown in Table 3.

    Table 3 IWGDF-IDSA system

    The presence of clinically significant foot ischemia makes both diagnosis and treatment of infection considerably more difficult.

    1. a.

      Infection refers to any part of the foot.

    2. b.

      In any direction, from the rim of the wound.

    3. c.

      If osteomyelitis is demonstrated in the absence of ≥ 2 signs/symptoms of local or systemic inflammation, classify the foot as either grade 3(O) (if < 2 SIRS criteria) or grade 4(O) if ≥ 2 SIRS criteria).

    Assessment of ulcer healing outcome clinically

    An Android smartphone was used to measure the ulcer’s length, breadth, and surface area exactly [33]. The camera was positioned 25 cm from the ulcer, making sure it was parallel to the wound. After taking the picture, the operator marked the edges of the wound and determined the size of the ulcer. A blinded medical practitioner assessed each wound three times to ensure reproducibility, and statistical analysis was performed using the average of these data [29]. Ulcer size reduction will be computed using the following formula: ulcer size reduction = (Ai – Af)/Ai × 100, where Ai is the initial ulcer area and Af is the ulcer area during follow-up after treatment. Ulcers were assessed and photographed for healing [34].

    Management of ulcer and application of WJ-MSC exosome gel

    Debridement of diabetic foot ulcers was initially performed to remove hyperkeratotic skin or necrotic and infected tissues. Following that, the area was cleaned with regular saline. Before beginning any research, measurements were made of the ulcer’s length, width, and surface. After applying the Wharton jelly derived mesenchymal stem cell (WJ-MSC) exosome gel to the ulcer, the treatment group covered the region with sterile gauze and a non-compressible bandage. After a month of doing every 3 days, the wound was irrigated with regular saline, examined for infection, and then treated with Wharton jelly derived mesenchymal stem cell (WJ-MSC) exosome gel. The SOC was administered to the control and placebo groups, which included removing necrotic, hyperkeratotic, and infected tissues, washing the wound with regular saline, and covering the ulcer with non-compressible bandages and sterile gauze. The patients were instructed to change the bandages every day and wipe the ulcer with regular saline [29].

    Follow-up

    Participants were followed up for 16 weeks with evaluations conducted at 2, 4 weeks, then 6 weeks, and then at 2, 4, and 6 months [29]. At each visit:

    1. 1.

      Ulcers were cleansed and assessed for infection.

    2. 2.

      A record of the interim medical history was kept, which included adverse events and prescription drugs.

    3. 3.

      Photographs of the ulcers were taken at each time point.

    Endpoints

    Primary Endpoint:

    Secondary Endpoints:

    • The average reduction in ulcer size throughout the research.

    • Complete healing rate (100% re-epithelialization without drainage).

    • Safety assessment, including adverse events and tolerability [29].

    Evaluation of outcomes

    The study utilized clinical classification systems, including the SINBAD and WIFI systems, to stratify ulcers by severity, vascular health, and infection risk. Evaluating an ulcer involves several diagnostic tools to uncover underlying complications. To provide a comprehensive picture of systemic health and inflammation, laboratory tests usually include fasting blood sugar levels, glycated hemoglobin (HbA1c), a full metabolic panel, complete blood count (CBC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).

    Imaging studies play a critical role, with plain X-rays used to identify hidden issues such as osteomyelitis, subcutaneous air, fractures, or foreign bodies. When osteomyelitis is suspected, MRI stands out as the preferred diagnostic tool due to its superior accuracy. Peripheral vascular disease can be assessed using arterial Doppler and ankle-brachial index (ABI) measurements, ensuring vascular factors are addressed. The probe-to-bone (PTB) test provides a straightforward but efficient way to identify osteomyelitis at the patient’s bedside: if a sterile metal probe contacts bone while exploring the ulcer, the test is positive. When treating diabetic individuals who may have bone infections, this rapid and accurate test is quite helpful [35].

    All patients in the three groups mentioned above were subjected to

    1. 1.

      To get rid of necrotic or diseased tissues, wounds were debrided.

    2. 2.

      After cleaning the region with regular saline, the therapy was administered.

    3. 3.

      The ulcers were covered with non-compressive bandages and sterile gauze.

    4. 4.

      Participants were instructed to clean and redress ulcers daily.

    Statistical analysis

    The non-parametric Wilcoxon rank-sum test was used to evaluate differences in continuous variables of interest, while the chi-square test (or Fisher’s exact, if more applicable) was employed to compare categorical variables between groups. The Wilcoxon signed-rank test was used for post hoc comparisons to find changes in ulcer area across the timepoints of interest, and the non-parametric Friedman test was used to find differences in ulcer size at baseline, 2 weeks, and 4 weeks for the effects of therapy. Software GraphPad Prism (GraphPad version 8.0.2) was used to conduct statistical analysis. When P was less than 0.05, statistical significance was reached.

    Continue Reading

  • GP Bullhound advised IMPECT on its acquisition by Catapult

    GP Bullhound advised IMPECT on its acquisition by Catapult

    Berlin, 13 October 2025 – GP Bullhound acted as the exclusive financial advisor to IMPECT, a global SportsTech data and analytics platform, on its acquisition by Catapult Group International Limited (ASX:CAT), a leading Australian sports performance technology company.

    Catapult will acquire 100% of IMPECT for up to €78 million and raise A$130 million underwritten institutional equity placement to finance the transaction and further strategic M&A.

    Founded in Germany in 2014, IMPECT is a pioneer in football analytics, known for its proprietary Packing® metric, and provides scalable, technology-first solutions that deliver deep tactical insights and advanced contextual data. Its products are used by more than 150 professional clubs across 25+ countries, enabling advanced scouting and tactical decision-making.

    Together, Catapult and IMPECT are building the future of sports performance technology – combining video, tactical, and performance data into a single, unified analytics ecosystem that enhances how teams approach player recruitment, tactical analysis, and performance optimization.

    This transaction reinforces GP Bullhound’s global leadership in SportsTech and data analytics, representing its tenth transaction in 18months in this exciting subsector of tech. Most recent transactions include the the $600m sale of Urban Sports Club to Wellhub, PerfectGym to Sport Alliance, or the acquisitions of Eversports by Verdane, and BRP Systems by Nordic Capital. GP Bullhound continues to build on its strong track record advising category leaders at the intersection of sport, data, and digital innovation.

    Simon Miremadi, Partner at GP Bullhound, said:
    “We are thrilled and incredibly proud to have advised the IMPECT team on this landmark transaction. Stefan, Jens, Lukas, Matthias and the entire IMPECT team have built a global company at the intersection of sport, data, and technology. Catapult is the ideal partner to accelerate IMPECT’s vision, impact and reach across multiple sports.”

    Stefan Reinartz, Co-founder and Managing Director of IMPECT, added:
    “From the moment our founders heard the vision from Will and the team, it became clear that bringing our technology into the Catapult platform represented an opportunity to accelerate our growth, benefit from Catapult’s global scale and industry leadership, whilst maintaining our steadfast culture of innovation. We are deeply grateful to the GP Bullhound team for their outstanding partnership and unwavering commitment throughout the process – their strategic guidance, precision, and relentless execution ensured a highly competitive process and an exceptional outcome for IMPECT.”

    About IMPECT
    IMPECT is a leading football video and data analytics company providing advanced insights to professional clubs and federations worldwide. Founded in 2014 in Germany, IMPECT’s proprietary data model quantifies and visualizes the complexity of football, offering revolutionary tools for player evaluation and tactical analysis.
    Learn more at www.impect.com.

    About Catapult
    Catapult (ASX: CAT) is a global leader in sports performance technology, helping athletes and teams improve performance through data, analytics, and wearable innovation. With headquarters in Australia and operations across the globe, Catapult’s products are trusted by elite teams across football, rugby, basketball, and beyond.
    Visit www.catapult.com.

    About GP Bullhound
    GP Bullhound is a leading technology advisory firm, providing transaction advice and capital to the world’s best entrepreneurs and founders. Founded in 1999 in London and Menlo Park, the firm today has 10 offices spanning Europe, Asia and the US.
    For more information, please visit www.gpbullhound.com.

    Enquiries
    For enquiries, please contact:
    Simon Miremadi, simon.miremadi@gpbullhound.com

    Continue Reading

  • TSMC Becomes AI Backbone as Nvidia and AMD Double Down

    TSMC Becomes AI Backbone as Nvidia and AMD Double Down

    This article first appeared on GuruFocus.

    Oct 13 – Taiwan Semiconductor (NYSE:TSM) continues to dominate headlines as its stock slices through new all-time highs, fueled by powerful waves of AI demand. In just a 6 month, the chip giant delivered nearly 80% total return, outpacing the S&P 500 by more than 20%. A jolt came last Friday: news of Trump’s threat of a 100% tariff on China triggered a 6% pullback, though underlying momentum in AI spending still looks firm.

    Hyperscale cloud players continue locking in deals to expand data center capacity ahead of demand. Oracle (NYSE:ORCL) saw its stock jump over 20% recently, backed by explosive year-over-year growth in multicloud database bookings. Its partnerships with Microsoft, Amazon (AMZN), and Google (NASDAQ:GOOGL) have powered that surge.

    Meanwhile, a major pivot in chip supply is likely underway. AMD (AMD) has inked a significant multi-year AI chip contract with OpenAI, agreed to supply about 6 gigawatts of capacity starting 2026, and granted OpenAI the option to acquire up to 10% of its shares. That deal reverberated across the sector, as AI buyers increasingly diversify beyond Nvidia (NASDAQ:NVDA). NVDA, in turn, earlier struck a $100 billion partnership with OpenAI to help build AI infrastructure at scale.

    TSM sits at the fulcrum of this shift: while chip designers like NVDA and AMD lean into R&D and architecture, they depend heavily on TSM for fabrication. Though Intel (NASDAQ:INTC) may try to reenter the race in the long term, its execution gaps leave it playing catch-up for now.

    With that perspective, the TSM FY2026 appears to be very strong due to a number of mega deals with leading chip manufacturers and cloud technology companies. The volatility in the near term could be due to trade-war headlines but the broad AI tailwinds are likely to keep pushing the demand. As market mood might waver, TSM remains at the centre of the next layer of AI infrastructure development due to its fundamental positioning in terms of chip design as well as manufacturing.

    Continue Reading

  • Veg oils prices commentary: futures edge mostly lower on higher CPO stocks, plummeting crude

    Veg oils prices commentary: futures edge mostly lower on higher CPO stocks, plummeting crude

    Crude palm oil (CPO) futures reversed direction after a three-day rally to close lower on Friday, as traders digested news from the September Malaysia data released by the Malaysian Palm Oil Board (MPOB) and amid positioning ahead of the weekend.

    The most-active December CPO futures contract on the Bursa Malaysia Derivatives Exchange fell by 0.98% to 4,546 ringgit ($1,077) per tonne after trading between 4,525-4,612 ringgit per tonne and extending losses from earlier in the day, when it closed 10 ringgit per tonne lower at 4,581 ringgit per tonne at the end of morning trading session.

    Losses were extended into the afternoon following data from MPOB which showed a build-up in stocks instead of a previously anticipated decline, though indications of better October exports helped to curb the drop in CPO futures.

    On a weekly basis, the most-active third month contract has rose by 2.34% compared with 4,591 ringgit per tonne on October 3, with support stemming mainly from news of Indonesia’s B50 biodiesel upgrade plans and movement in related oils.

    Chinese vegoil futures closed mixed on Friday after strong increases the previous day, with the most-active January palm olein futures contract on the Dalian Commodity Exchange falling by 0.78% to 9,438 yuan ($1,323) per tonne as it tracked a similar movement with Malaysia palm oil futures.

    The January soybean oil futures on DCE was marginally higher by 8 yuan per tonne to 8,302 yuan per tonne, while the January rapeseed oil futures on the Zhengzhou Commodity Exchange fell by 1.33% to close at 10,061 yuan per tonne.

    On the news front, Malaysia’s palm oil stocks rose for a seventh straight month to 2.36 million tonnes at the end of September, against earlier average market estimates of 2.15 million-2.16 million tonnes, with the resultant increase due to smaller-than-expected declines in production, higher imports and lower local disappearance.

    CPO production was marginally lower by 0.73% to 1.841 million tonnes, while exports rose by 7.69% to 1.43 million tonnes. Imports were recorded at 78,413 tonnes, up by 34% on the month, while local disappearance fell by 33% to 333,432 tonnes.

    Meanwhile, cargo surveyors Intertek Testing Services (ITS) and Amspec Agri Malaysia reported October 1-10 exports for Malaysia at 523,602 tonnes and 495,415 tonnes respectively, 9.86% and 19.4% higher from their respective September estimates. The increase helped limit losses in CPO futures amid optimism for stronger October export demand.

    In the cash market, CPO was traded at $1,162 per tonne CFR Kandla for October shipment and at $1,170 per tonne CFR east coast India for November-December shipment.

    Offers heard toward the close of the day were at $1,165-1,170 per tonne CFR west coast India (WCI) for October cargoes, while offers for November shipment were around $1,175-1,185 per tonne CFR WCI and $1,185 per tonne CFR WCI for December shipment.

    At origin, CPO offers out of Indonesia were limited, while offers for olein were at $1,100 per tonne FOB Indonesia for November shipment, with a trade at $1,095 per tonne FOB Indonesia also heard concluded earlier in the day for November shipment.

    Soyoil futures

    In the Americas, soyoil futures plummeted in the Chicago Mercantile Exchange, borrowing weakness from crude markets.

    Soyoil CME futures for December delivery declined by 2.22% day on day to 49.84 cents per lb at 1pm US Eastern time, erasing weekly increases.

    Crude prices weighed on the soyoil market, with Brent and West Texas Intermediate contracts down by 3.7-4.2% day on day amid risk-off positioning backed by progress in peace negotiations for the conflict in the Gaza Strip.

    The US soybean market also faced headwinds from what seems to be a deteriorating atmosphere for trade negotiations between the US and China. China has been strict on the limitations to its rare earths exports and has imposed retaliatory charges on US vessels docking at Chinese ports, while US President Donald Trump threatened to cancel the meeting he is scheduled to have with Chinese President Xi Jinping in three weeks’ time.

    The US dollar reversed directions from the previous trading day, devaluating when measured against a basket of reserve currencies and putting an end to a four-day rally. This helped capping soyoil losses somewhat.

    December CME soymeal futures fell slightly to $276 per short ton at 1pm US Eastern time, with some underlying support from product spreading dynamics.

    In the physical market in South America, the bases negotiations for both soyoil and soymeal were slower with the holiday in Argentina.

    The November basis was assessed at a discount of 0.75 cents per lb in Argentina and at a premium of 0.90 cents per lb in Brazil, both to December futures.

    On the soymeal front, the November basis was assessed at a discount of $7.50 per short ton in Brazil, while in Argentina the corresponding basis was assessed at a discount of $11.50 per short ton to the same futures contract.

    As of 6:15pm Central European time, Euronext November rapeseed futures were trading at €467.25 ($542) per tonne, down by €4.50 per tonne from the previous session.

    FOB Rotterdam rapeseed oil prices fell on Friday.

    For the November–December–January (NDJ) window, offers were made at €1,087-1,093 per tonne, compared with €1,090-1,105 per tonne on Thursday October 9, while bids were made at €1,061-1,065 per tonne, compared with €1,070 per tonne on Thursday.

    For the February-March-April (FMA) window, offers were made at €1,058-1,070 per tonne and bids were made at €1,048-1,050 per tonne, compared with offers of €1,065-1,082 per tonne and bids at €1,055-1,060 per tonne on Thursday.

    Rapeseed oil was heard to have traded at €1,054 per tonne for the FMA window on Friday.

    FOB sunflower oil prices across six EU ports eased on Friday in a correction after hitting nearly three-year highs.

    For the November-December window, offers were made at $1,355 per tonne with bids of $1,330 per tonne, compared with offers made at $1,360-1,390 per tonne and bids of $1,340 per tonne on Thursday.

    For the January–February–March (JFM) window, offers were made at $1,325 per tonne and drew bids of $1,310 per tonne, compared with offers of $1,327.50-1,330.00 per tonne and bids of $1,300.00-1,322.50 per tonne on Thursday.

    No sunflower oil trades were heard on Friday.

    Black Sea sunflower oil

    The Black Sea sunflower oil market recorded limited activity on Friday, with October–November offers reported around $1,300 per tonne CIF Mersin/Iskenderun. Buyers, recognizing that earlier levels were no longer workable, have raised ideas into the $1,275–1,285 per tonne range compared with softer levels earlier in the week.

    TMO has issued an international tender for 18,000 tonnes of sunflower oil for November delivery. The tender is scheduled for Thursday October 16. In its previous tender on September 12, TMO awarded 18,000 tonnes of crude sunflower oil for October delivery — 6,000 tonnes to Tekirdag at $1,256 per tonne CFR and 12,000 tonnes to Iskenderun/Mersin at $1,253.80 per tonne CFR.

    In other news, Russia’s Agriculture Ministry has revised down its 2025 sunflower harvest forecast to 17.5 million tonnes, compared with 18.3 million tonnes in 2024. The downgrade reflected weaker yields, particularly in the southern regions, despite expectations of record gross production across several other crops this season.

    Fastmarkets’ comprehensive coverage includes a wide range of veg oils and meals, including palm, coconut, cottonseed, peanut, sunflower and canola. Our dedicated team of price reporters and analysts monitors these markets daily to provide you with the most up-to-date pricing information.

    Continue Reading

  • Welcome to the Agentic Enterprise: With Agentforce 360, Salesforce Elevates Human Potential in the Age of AI – Salesforce Investor Relations

    1. Welcome to the Agentic Enterprise: With Agentforce 360, Salesforce Elevates Human Potential in the Age of AI  Salesforce Investor Relations
    2. Exclusive: Salesforce announces agents with voice and hybrid reasoning  Axios
    3. Salesforce adds voice calling to Agentforce AI customer service software  CNBC
    4. Salesforce Unveils IT Product, Deepening ServiceNow Rivalry  Bloomberg.com
    5. Salesforce Enhances AI Capabilities with New Data Governance Innovations  Small Business Trends

    Continue Reading

  • Report: COVID-19 Vax Risks Managed, Independence Important – Medscape

    1. Report: COVID-19 Vax Risks Managed, Independence Important  Medscape
    2. CDC’s Vaccine Safety Monitoring Office Performed Well During COVID-19 Pandemic; Steps Needed to Safeguard Office’s Independence, Improve Communications  National Academies
    3. CDC’s Vaccine Safety Office Has an Image Problem, Report Says  MedPage Today

    Continue Reading